Showing results (2331-2340 of 8,257) with videos related to

Sort By:
Pageof 826
Haematologica|September 1, 1991
Idarubicin in blastic crisis of chronic myelogenous leukemiaG Lambertenghi-Deliliers, C Annaloro, M Cortellaro, et al.
Haematologica|September 1, 1991
Severe neutropenia in a patient with large granular lymphocytosis: prolonged successful control with cyclosporin AV Garipidou, C Tsatalas, Z Sinacos
Haematologica|September 1, 1991
Recombinant interferon alpha-2B for acute post-transfusion hepatitis in acute myeloid leukemiaP Almasio, S Mirto, C Malleo, et al.
Haematologica|March 15, 2006
The effect of a novel recombination between the homeobox gene NKX2-5 and the TRD locus in T-cell acute lymphoblastic leukemia on activation of the NKX2-5 geneGrzegorz K Przybylski, Willem A Dik, Piotr Grabarczyk, et al.
Haematologica|March 15, 2006
The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysisJosee Golay, Chiara Cortiana, Massimiliano Manganini, et al.
Haematologica|March 15, 2006
Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironmentDiana Campioni, Sabrina Moretti, Luisa Ferrari, et al.
Haematologica|March 15, 2006
Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblastsNorbert Grzasko, Anna Dmoszynska, Marek Hus, et al.
Haematologica|March 16, 2006
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicityErcole Brusamolino, Chiara Rusconi, Luigi Montalbetti, et al.
Haematologica|March 1, 2006
Iron regulatory proteins 1 and 2 in human monocytes, macrophages and duodenum: expression and regulation in hereditary hemochromatosis and iron deficiencyStefania Recalcati, Alessandra Alberghini, Alessandro Campanella, et al.
Haematologica|March 1, 2006
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-pointsAngela Dispenzieri, Morie A Gertz, Martha Q Lacy, et al.
Pageof 826